ClinicalTrials.gg
RecruitingNCT03994029Updated Jan 23, 2024

Effect of Polyphenol Supplementation on Hepatic Steatosis and Vascular Compliance

An interventional study of Effect of polyphenols on hepatic steatosis and vascular elastography and intima media thickness in Obesity, Childhood, Hepatic Steatosis and Intimal Hyperplasia, sponsored by St. Justine's Hospital. Recruiting at 1 site in Canada. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2024-01-23.

Sponsored by St. Justine's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Jul 2021; still recruiting 5 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Pediatric Obesity with a site in Canada — 7 open to participants now, 9 under way, 1 of them phase 3. Pediatric Obesity · Canada.

Planned enrollment
23rd of 40
60 · median 73
Started
2021
with 5 others
No phase
37 of 51
6 open now
Registered
35th of 51
by date

Among the 51 studies in Pediatric Obesity with a site in Canada, this one is the 23rd largest by planned enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2021, is one of 37 with no phase, and was the 35th registered.

Pediatric Obesity

1,132 studies on the registry are indexed under Pediatric Obesity; 183 are open to participants now.

Browse Pediatric Obesity studies →

Open to participants now

7 of the 51 studies in Pediatric Obesity with a site in Canada are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 119 Pediatric Obesity studies recruiting now, 16 (13%) set no upper age limit and 101 (85%) stop at 75 or younger; 110 take children under 18; 67 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Pediatric Obesity with a site in Canada, or all of them as a file.
02

Study summary

The main objective is to study the effect of polyphenol supplementation on hepatic steatosis as measured by hepatic ultrasound, hepatic magnetic resonance imaging and on intima-media thickness and vascular elastography in obese adolescents known for hepatic steatosis as diagnosed by liver biopsy

Read the detailed description
  1. Evaluate the feasibility of a larger, open-label, randomized, controlled trial on the effects of polyphenol supplementation:

    Recruitment, compliance to polyphenol supplementation and the visit roadmaps Duration of the radiological exams and participants' satisfaction and point of view on the experience. Test the relevance of using a food diary. Test the effectiveness of the data collection procedure during the visits. Explore the obstacles encountered while performing the radiological exams and the rate of adverse events (AE). Calculate the sample size of the future randomized clinical study

  2. Effects of polyphenols IMT and vascular elastography. Anthropometric measurements, insulin resistance, inflammation, lipid/lipoprotein profile, gut microbiome and liver function
  3. Evaluated different imaging modality for steatosis Different imaging modalities will be compared between children
03

Conditions studied

  • Obesity, Childhood
  • Hepatic Steatosis
  • Intimal Hyperplasia
04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 12 to 18 years
  • percentile > 85th for age and sex
  • Diagnosis of hepatic steatosis on imaging (ultrasound or MR).
  • Diagnosis of hepatic steatosis, NASH, or fibrosis on liver .
  • Elevated (ALT) enzyme level.
  • Index of hepatic steatosis 8xALT/AST + BMI (+2 for girls) > 30.

Exclusion criteria

Exclusion Criteria:

  • Known chronic systematic diseases
  • Any other serious conditions which, according to the doctor's judgment, would prevent compliance and safe participation in the study until completion.

Exclusion criteria to be validated when contacting the participants and their parents/tutors:

  • Being pregnant.
  • Taking all kinds of prescription or over-the-counter natural health products/natural supplements/vitamins on an ongoing basis or within the next four months, excluding vitamin D.
  • Weight loss of 5% to 10% of the usual weight in the last six months before recruitment or weight change of 5% in the last three months.
  • Alcohol consumption > two drinks/day or > one day/week.
  • Known peanut allergy and/or to the medicinal ingredients contained in the active polyphenol supplement: elderberry, haskap, black chokeberry, blueberry, blackcurrant.
  • Any for MRI.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Polyphenol supplementation

    120mg per day of powder polyphenol for 60 days

    Dietary Supplement: Effect of polyphenols on hepatic steatosis and vascular elastography and intima media thickness

  • Placebo comparator
    Placebo

    1 tab PO QD per day of placebo for 60 days

    Dietary Supplement: Effect of polyphenols on hepatic steatosis and vascular elastography and intima media thickness

Interventions

  • Dietary supplementEffect of polyphenols on hepatic steatosis and vascular elastography and intima media thickness

    Measurement of effect of polyphenol supplementation vs placebo on hepatic steatosis and vascular elastography and intima media thickness

06

What researchers measure

Primary outcomes

  1. Recruitment

    Rate of recruitment

    Time frame: Through study completion an average of 1 year

  2. Retention:

    The percentage of adolescents who agree to participate in the study and the retention

    Time frame: Through study completion an average of 1 year

  3. Compliance with polyphenol supplementation

    Percentage of compliance

    Time frame: Through study completion an average of 1 year

  4. Effectiveness of the data collection procedure during the visits

    Percentage of completed visits

    Time frame: Through study completion an average of 1 year

  5. Adverse event

    Percentage of adverse events

    Time frame: Through study completion an average of 1 year

  6. Satisfaction of the participants and their point of view on the experience

    Percentage of satisfaction of participants enrolled

    Time frame: Through study completion an average of 1 year

  7. Sample size calculation for a randomized controlled study

    A sample size for a future randomized controlled study will be calculated from the estimates obtained during this pilot study.

    Time frame: Through study completion an average of 1 year

Secondary outcomes

  1. Change in hepatic steatosis MR

    mDixonQuant in percentage

    Time frame: At recruitment, after 60 days, and after 120 days

  2. Change in hepatic steatosis B-mode US

    US liver echogenicity normal or increased

    Time frame: At recruitment, after 60 days, and after 120 days

  3. Change in intima media thickness (vascular compliance)

    Measurement of carotid artery intima media thickness in mm

    Time frame: At recruitment, after 60 days, and after 120 days

  4. Metabolic syndrome

    Insulin resistance evaluated by HOMA-IR mg\\dl

    Time frame: At recruitment, after 60 days, and after 120 days

  5. Cholesterol

    Triglyceride index (no unit)

    Time frame: At recruitment, after 60 days, and after 120 days

  6. Anthropometric measure

    Body mass index

    Time frame: At recruitment, after 60 days, and after 120 days

  7. Inflammatory marker 1

    CRP

    Time frame: At recruitment, after 60 days, and after 120 days

  8. Inflammatory marker 2

    TNF alpha

    Time frame: At recruitment, after 60 days, and after 120 days

  9. Inflammatory marker 3

    IL-6

    Time frame: At recruitment, after 60 days, and after 120 days

  10. Lipid markers 1

    Triglycerides

    Time frame: At recruitment, after 60 days, and after 120 days

  11. Lipid markers 2

    LDL

    Time frame: At recruitment, after 60 days, and after 120 days

  12. Lipid markers 3

    HDL

    Time frame: At recruitment, after 60 days, and after 120 days

  13. Lipid markers 4

    Apo AI

    Time frame: At recruitment, after 60 days, and after 120 days

  14. Lipid markers 5

    Apo B-100

    Time frame: At recruitment, after 60 days, and after 120 days

  15. Lipid markers 6

    Adiponectin, leptin

    Time frame: At recruitment, after 60 days, and after 120 days

  16. Liver function test

    ALT

    Time frame: At recruitment, after 60 days, and after 120 days

  17. Stool test

    Gut microbiome composition

    Time frame: At recruitment, after 60 days, and after 120 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Dec 2024, 41 months after the start.

Of 542 non-industry interventional studies with no phase under Pediatric Obesity, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 45. This study's planned 41 months is above that.

Counting every sponsor, half of 544 studies reached it within 25 months; a quarter within 11 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2019
First posted
Jun 21, 2019
StartActual
Jul 4, 2021
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Jan 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03994029
Responsible party
Ramy El Jalbout (Assistant professor, St. Justine's Hospital) — Principal investigator
First posted
Jun 21, 2019
Start date
Jul 4, 2021
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Jan 23, 2024

Study contacts

Principal investigator
Contact
ramy.el-jalbout.hsj@ssss.gouv.qc.ca
5143454931
Ramy El Jalbout, MD MSc
principal investigator · St. Justine's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion